Skip to main content
. Author manuscript; available in PMC: 2018 Aug 20.
Published in final edited form as: Cancer Res. 2016 Oct 28;77(1):198–206. doi: 10.1158/0008-5472.CAN-16-1151

Figure 5.

Figure 5.

Correlation between relative survival prolongation for PDX mouse models treated with temozolomide (TMZ) and predicted percent control growth for PDX models treated with temozolomide calculated from model #4 (A) or model #6 (B and C). In C, PDX models were restricted to those expressing low levels of MGMT (black dots). Cells with low MGMT levels were defined as those for which the average percentage of reporter expression for the MGMT assay was at least 50%; this value of percentage of reporter expression was observed previously for a cell line that is known to be MGMT deficient (TK6). PDX models with higher levels of MGMT reporter expression are represented with open squares.